Carr A, Samaras K, Burton S.
et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin
resistance in patients receiving HIV protease inhibitors. AIDS.1998;12:F51-F58.
Miller KD, Jones E, Yanovski JA.
et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet.1998;351:871-875.
Lo JC, Mulligan K, Tai VW.
et al. "Buffalo hump" in men with HIV-1 infection. Lancet.1998;351:867-870.
Carr A, Samaras K, Thorisdottir A.
et al. Diagnosis, prediction and natural course of HIV protease inhibitor-associated
lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet.1999;353:2093-2099.
Lichtenstein KA, Ward DJ, Moorman AC.
et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory
Thiebaut R, Daucourt V, Mercie P.
et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus
infection. Clin Infect Dis.2000;31:1482-1487.
Martinez E, Mocroft A, Garcia-Viejo MA.
et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease
Duran S, Savs M, Spire B.
et al. Failure to maintain long-term adherence to highly active antiretroviral
Zhang B, MacNaul K, Szalkowski D.
et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab.1999;84:4274-4277.
Lenhard J, Weiel JE, Paulik MA, Furfine ES. Stimulation of vitamin A1 acid signaling by the HIV protease
inhibitor indinavir. Biochem Pharmacol.2000;59:1063-1068.
Caron M, Auclair M, Vigouroux C.
et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding
protein-1 intranuclear localization, inhibits preadipocyte differentiation,
and induces insulin resistance. Diabetes.2001;50:1378-1388.
Gervasoni C, Ridolfo AL, Trifirò G.
et al. Redistribution of body fat in HIV-infected women undergoing combined
antiretroviral therapy. AIDS.1999;13:465-472.
Madge S, Kinloch-de-Loes S, Mercey D.
et al. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS.1999;13:735-737.
Saint-Marc T, Partisani M, Poizot-Martin I.
et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving
long-term nucleoside analogue therapy. AIDS.1999;13:1659-1667.
Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated
with HIV nucleoside analogue therapy. AIDS.2000;14:F25-F32.
Mallal SA, John M, Moore CB.
et al. Contribution of nucleoside analogue reverse transcriptase inhibitors
to subcutaneous fat wasting in patients with HIV infection. AIDS.2000;14:1309-1316.
Parker RA, Meyers DS, Andrews Flint OP, Durham SK. Effects of nucleoside reverse transcriptase inhibitors on adipogenesis
and adipocyte metabolism. From: 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy
in HIV; September 13-15, 2000; Toronto, Ontario. Abstract O4.
White A, John M, Moore C.
et al. Raised lactate levels are common and may be predictive of subcutaneous
fat wasting. From: 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy
in HIV; September 13-15, 2000; Toronto, Ontario. Abstract P82.
Shikuma CM, Hu N, Milne C.
et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected
individuals with peripheral lipoatrophy. AIDS.2001;15:1801-1809.
Carr A, Hudson J, Chuah J.
et al. HIV protease inhibitor substitution in patients with lipodystrophy. AIDS.2001;15:1811-1822.
Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic
abnormalities in patients suffering from lipodystrophy. AIDS.1999;13:2188-2189.
Smith D, Carr A, Law M.
et al. A randomised trial of thymidine analogue withdrawal in lipoatrophic
HIV patients virologically controlled on protease inhibitor sparing therapy. From: 1st International Conference on AIDS Pathogenesis and Treatment;
July 8-11, 2001; Buenos Aires, Argentina. Abstract 96.
Johnson AA, Ray AS, Hanes J.
et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial
DNA polymerase. J Biol Chem.2001;276:40847-40857.
US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. Available at: http://hivatis.org/trtgdlns.html#Adult.
Accessed June 11, 2002.
Smith D, Goggin L, Meldrum H.
et al. Capturing the paradigm shift in HIV treatment. AIDS Care.2000;12:41-47.
Carr A, Chuah J, Hudson J.
et al. A randomised, open-label comparison of three highly active antiretroviral
therapy regimens including two nucleoside analogues and indinavir for previously
untreated HIV-1 infection. AIDS.2000;14:1171-1180.
Hetherington S, McGuirk S, Powell G.
et al. Hypersensitivity reactions during therapy with the nucleoside reverse
transcriptase inhibitor abacavir. Clin Ther.2001;23:1603-1614.
Kind P, Dolan P, Gudex C.
et al. Variations in population health status. BMJ.1998;316:736-741.
AVANTI Steering Committee. Analysis of HIV-1 clinical trials. Lancet.1999;353:2061-2064.
Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet.2000;356:1423-1430.
Kotler DP, Rosebaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and
control subjects. J Acquir Immune Defic Syndr Hum Retrovirol.1999;20:228-237.
Arioglu E, Duncan-Morin J, Sebring N.
et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy
syndromes. Ann Intern Med.2000;133:263-274.